The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
lei kang xin lv shi chang xin yao almokalant de dian yao li xue he yao dong xue
Author(s): 
Pages: 371
Year: Issue:  6
Journal: World Clinical Drugs

Keyword:  抗心律失常Almokalant单相动作电位室性早搏室性心律失常持续性室速药动学β受体Holter正性肌力作用;
Abstract: <正> Almokalant是一个新的Ⅲ类抗心律失常药。它延长心房/心室的单相动作电位和不应期,不影响传导速度,具有正性肌力作用,无β受体阻滞效应。 10例恢复期心肌梗塞伴室性心律失常患者,在24小时Holter监测中室性早搏次数≥720次或非持续性室速发作≥10次。随机静脉滴注almokalant 4.5mg(12.8μmol)或安慰剂,10分钟滴完;次日两者交换。滴注almokalant前后,心率、心电图PR间期和QRS时限无明显变化。滴注后,QTc间期由445±15延长至548±53毫秒(p=0.0015),持续120分钟;室性早搏的联
Related Articles
No related articles found